Filing Flows › Health Care › Bristol Myers Squibb (BMY)

Bristol Myers Squibb (BMY) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · Bristol Myers Squibb (BMY) Q3 2026 earnings results →

Q3 2026 Revenue up 7% year over year to $13.1B · 17¢ of every $1 of revenue kept as net profit · operating margin 19.4%

Bristol Myers Squibb made $13.1B in Q3 2026 (+7% Y/Y): Net product sales $12.6B, Camzyos $420M. Operating margin 19.4%, net earnings $2.2B. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.

Revenue$13.1B

Year over year+7%

Operating margin19.4%

Net earnings$2.2B

Operating cash flow$4.2B

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $13.1B in Q3 2026, up 7% year over year and up 1% from the previous quarter. Legacy Portfolio was the largest line at 41% of revenue. Eliquis added $0.94B year over year (up 25%), 111% of the total change.

Operating profit was $2.5B, a 19.4% margin (down 6.1 points year over year). Operating profit fell $0.58B even though revenue rose $0.85B versus Q3 2025, so costs grew faster than sales. Total costs grew 16% against revenue growth of 7%. The fastest-growing cost line was Other operating costs (+71%). Net earnings were $2.2B, down 2% year over year. The effective tax rate was 14.7%.

Operating cash flow was $4.2B (down 34% year over year), 193% of net earnings. Non-cash charges added back $0.63B of depreciation and amortization and $0.14B of share-based compensation. Working capital and other items added $1.3B. Capital expenditures of $0.34B left free cash flow of $3.8B.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q3 2026	10-Q	Oct 29, 2026	$13.1B	+7%	19.4%	$2.2B	$4.2B
Q2 2026	10-Q	Jul 30, 2026	$13.0B	+6%	31.5%	$3.3B	$3.4B
Q1 2026	10-Q	Apr 30, 2026	$11.5B	+3%	28.2%	$2.7B	$1.1B
Q4 2025	10-K	Feb 11, 2026	$12.5B	+1%	11.8%	$1.1B	$2.0B
Q3 2025	10-Q	Oct 30, 2025	$12.2B	+3%	25.5%	$2.2B	$6.3B
Q2 2025	10-Q	Jul 31, 2025	$12.3B	+0.6%	14.5%	$1.3B	$3.9B
Q1 2025	10-Q	Apr 24, 2025	$11.2B	-6%	26.5%	$2.5B	$2.0B

Charts

Latest (Q3 2026): Y/Y +7%, Q/Q +1%.

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q3 2026): Net income $2.2B, Operating cash flow $4.2B.

-9.7% since FY2020: buybacks shrank the count.

Cash $10.2B, short-term investments $464M, long-term debt $44.8B at 2025-12-31.

Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.